阿伐曲泊帕治疗化疗所致血小板减少症患者:病例系列
该病例系列报告了6例实体瘤合并化疗所致血小板减少症(CIT)患者,结果支持阿伐曲泊帕(AVA)在提高血小板计数和减少CIT对肿瘤治疗影响方面的临床获益,使患者无需减量或中断治疗即可继续化疗。
要点
- 6例实体瘤合并CIT患者接受阿伐曲泊帕治疗。
- 结果支持AVA提高血小板计数并减少CIT对肿瘤治疗的影响。
- 患者得以在不减量、不中断治疗的情况下继续化疗。
核心结论
- 这些病例的结果支持AVA在提高血小板计数和减少CIT对肿瘤治疗影响方面的临床获益,使患者无需减量或中断治疗即可继续化疗。
研究设计与样本
- 病例系列,纳入6例实体瘤合并CIT患者。
主要发现
- 6例实体瘤合并CIT患者的结果支持AVA提高血小板计数并减少CIT对肿瘤治疗的影响,使患者无需减量或中断治疗即可继续化疗。
关键数值与推荐
- 一项AVA的III期试验显示实体瘤合并CIT患者的血小板计数增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Management of chemotherapy-induced thrombocytopenia (CIT) is challenging, often resulting in chemotherapy treatment delays, dose reduction, and treatment interruption. Randomized trials support the potential efficacy and safety of thrombopoietin receptor agonists in CIT management. A phase III trial of avatrombopag (AVA) demonstrated increased platelet counts (PC) in patients with solid tumours experiencing CIT. To complement those findings, this case series of six patients with solid tumours and CIT is presented. Results from these cases support the clinical benefit of AVA in improving PC and reducing the impact of CIT on tumour treatment, allowing continued therapy without dose reduction or treatment interruption.
引用
- Galamaga R, Johnston S, Acosta C, et al. Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: A case series. Br J Haematol. 2024. PMID: 39434457. doi:10.1111/bjh.19797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。